Combining properties of different classes of PI3Kα inhibitors to understand the molecular features that confer selectivity

The Biochemical Journal
Grace Q GongJack U Flanagan

Abstract

Phosphoinositide 3-kinases (PI3Ks) are major regulators of many cellular functions, and hyperactivation of PI3K cell signalling pathways is a major target for anticancer drug discovery. PI3Kα is the isoform most implicated in cancer, and our aim is to selectively inhibit this isoform, which may be more beneficial than concurrent inhibition of all Class I PI3Ks. We have used structure-guided design to merge high-selectivity and high-affinity characteristics found in existing compounds. Molecular docking, including the prediction of water-mediated interactions, was used to model interactions between the ligands and the PI3Kα affinity pocket. Inhibition was tested using lipid kinase assays, and active compounds were tested for effects on PI3K cell signalling. The first-generation compounds synthesized had IC50 (half maximal inhibitory concentration) values >4 μM for PI3Kα yet were selective for PI3Kα over the other Class I isoforms (β, δ and γ). The second-generation compounds explored were predicted to better engage the affinity pocket through direct and water-mediated interactions with the enzyme, and the IC50 values decreased by ∼30-fold. Cell signalling analysis showed that some of the new PI3Kα inhibitors were more active in ...Continue Reading

References

Apr 4, 1997·Journal of Molecular Biology·G JonesR Taylor
Nov 1, 2001·Annual Review of Cell and Developmental Biology·R KatsoM D Waterfield
Mar 16, 2004·Science·Yardena SamuelsVictor E Velculescu
Apr 16, 2004·American Journal of Physiology. Cell Physiology·Yoshihiro TaniyamaKathy K Griendling
May 25, 2004·Journal of Chemical Information and Computer Sciences·Marcel L VerdonkPaul Watson
Mar 24, 2005·Journal of Cellular and Molecular Medicine·Gang SongShideng Bao
Sep 30, 2005·Journal of Medicinal Chemistry·Marcel L VerdonkRobin Taylor
Jan 2, 2008·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Jaclyn LoPiccoloPhillip A Dennis
Sep 17, 2008·Oncogene·L Zhao, P K Vogt
Jan 9, 2010·Acta Crystallographica. Section D, Biological Crystallography·Vincent B ChenDavid C Richardson
Jan 19, 2010·Nature Chemical Biology·Alex BerndtRoger L Williams
Apr 10, 2010·Nature Reviews. Molecular Cell Biology·Bart VanhaesebroeckBenoit Bilanges
Jun 15, 2010·Current Topics in Microbiology and Immunology·Jonathan M Backer
Aug 18, 2010·Proceedings of the National Academy of Sciences of the United States of America·Minghao SunPeter K Vogt
Jan 11, 2011·Molecular Cancer Therapeutics·Filip JankuRazelle Kurzrock
Sep 16, 2011·Journal of Chemical Information and Modeling·Daniel CappelChristoph A Sotriffer
Sep 20, 2011·Bioorganic & Medicinal Chemistry Letters·Samantha J HughesDavid G Brown
Oct 20, 2011·Science Signaling·Oscar VadasRoger L Williams
Dec 2, 2011·Neoplasia : an International Journal for Oncology Research·Euan A StronachHani Gabra
Dec 20, 2011·Bioorganic & Medicinal Chemistry·Jackie D KendallPeter R Shepherd
Dec 20, 2011·Bioorganic & Medicinal Chemistry·Jackie D KendallPeter R Shepherd
Feb 24, 2012·Nature Reviews. Molecular Cell Biology·Bart VanhaesebroeckPhillip Hawkins
May 1, 2012·Nature Chemical Biology·Giovanna BergaminiGitte Neubauer
Jul 24, 2012·Bioorganic & Medicinal Chemistry Letters·Kathryn BellGitte Neubauer
Aug 7, 2012·Bioorganic & Medicinal Chemistry Letters·Ian BruceLewis Whitehead
Jan 31, 2013·Journal of Medicinal Chemistry·Mariana NachtJuswinder Singh
Feb 13, 2013·Nature Reviews. Clinical Oncology·Jordi RodonJosep Tabernero
May 25, 2013·American Journal of Physiology. Cell Physiology·Jin-Jing YaoYan-Ai Mei
Jun 4, 2013·Bioorganic & Medicinal Chemistry Letters·Pascal FuretGiorgio Caravatti
Jul 4, 2013·Bioorganic & Medicinal Chemistry Letters·Sabina PecchiCharles F Voliva
Aug 2, 2013·Science Translational Medicine·Moshe ElkabetsJosé Baselga
Dec 3, 2013·Nature Chemical Biology·Nicholas M Levinson, Steven G Boxer
Jan 24, 2014·Biochemical Society Transactions·Jack U Flanagan, Peter R Shepherd
Mar 13, 2014·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Richard Wa Mackenzie, Bradley T Elliott
Apr 24, 2014·Journal of Medicinal Chemistry·Philip N CollierAlex M Aronov

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.